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INTRODUCTION-CONCEPTS AND  
APPROACHES
Severe mental illness represents a huge burden to society, 
reflecting the limited efficacy of current treatment for schizo-
phrenia, bipolar disorder and major depressive disorder. The 
antipsychotic drugs, developed for the treatment of schizo-
phrenia, are increasingly used for the treatment of mania in 
bipolar disorder, in which the evidence indicates they are the 
most effective therapy.
1 They may also be used in treating a 
variety of behavioural problems associated with disorders 
from childhood to the elderly; in total well over 1% of the ad-
ult population now receive antipsychotic drug treatment. Wh-
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ile some people with schizophrenia respond well to antipsy-
chotic drug treatment, a similar proportion (approximately one 
third) show little amelioration of their symptoms, while the 
remainder present varying degrees of symptom improve-
ment. Treatment adherence is a frequently underestimated 
factor that contributes to this substantial variability and which 
can be influenced by the emergence of adverse drug effects, al-
though patients taking their medication as prescribed can still 
show profound differences in response. There is little under-
standing of the underlying reasons for these individual differ-
ences, although accumulating evidence over the past 15 years 
indicates that genetic factors contribute substantially to the 
extent of symptom improvement following drug treatment. 
Studies of siblings and twins have provided some evidence 
in support of genetics influencing the response to antipsycho-
tic drugs. Thus symptom improvement following clozapine
2 
and olanzapine
3 has shown strong concordance in monozy-
gotic twin pairs. Identifying the genetic factors responsible 
for individual variability in the effects of drug treatment is the 
aim of pharmacogenetics. The pharmacogenetics of antipsy-
chotic drugs has received substantial research effort over the 
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Antipsychotic drugs are limited in their efficacy by the relatively poor response of negative and cognitive symptoms of schizophrenia as 
well as by the substantial variability in response between patients. Pharmacogenetic studies have sought to identify the genetic factors that 
underlie the individual variability in response to treatment, with a past emphasis on dopamine and serotonin receptors as candidate genes. 
Few studies have separated effects on positive and negative symptoms, despite the established differences in response to drug treatment 
between these syndromes. Where this has been done most findings are consistent with the conclusion that dopamine receptor polymor-
phisms relate to positive symptom response, while negative symptom improvement is influenced by polymorphisms of genes involved in 
5-HT neurotransmission. A wide range of polymorphisms in other candidate genes have been investigated, with some positive findings in 
those genes associated with glutamatergic transmission and/or risk factors for schizophrenia. However, there remains a lack of good rep-
licated findings; furthermore there is little evidence to support drug-specific genetic associations with treatment response. While most 
past studies focused on single candidate genes, technology now permits genome-wide association studies with response to antipsychotics. 
Although not without major limitations, these “hypothesis-free” approaches are beginning to identify further important risk factors for 
treatment response. Again there is little consistency between various studies, although some of the polymorphisms identified are in genes 
involved in neurodevelopment, which is increasingly being recognized as important in the pathophysiology of schizophrenia.
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past decade, driven by an awareness of the varied and often 
limited effectiveness of these drugs both in controlling symp-
toms of schizophrenia and in inducing adverse effects. 
This review will address progress in the pharmacogenetics 
of antipsychotic response, an important target for study given 
the high proportion of patients in whom antipsychotic treat-
ment is less that optimally effective. The inadequate response 
to treatment is more apparent in subgroups of symptoms; wh-
ile antipsychotic drugs are often effective at controlling the 
positive psychotic symptoms, they are less able to ameliorate 
the negative and cognitive features of schizophrenia. These in-
clude social withdrawal, blunted mood, lack of self care and de-
ficits in executive function and working memory which, along 
with depressed mood, are the symptoms that are most prob-
lematic in integrating the patient into society. 
By far the great majority of pharmacogenetic studies of an-
tipsychotic drug response have been performed in the context 
of schizophrenia, and the current review will be limited to 
this topic. It will not be a comprehensive listing of all pharma-
cogenetic results relating to individual differences in symptom 
response, but the major genes of interest will be mentioned, 
particularly where they have given rise to further pharmaco-
genetic study. Thus the review will aim to illustrate the current 
status of the field, with examples as well as reference to more 
specific review articles, primarily focusing on pharmacody-
namic rather than pharmacokinetic influences on drug action. 
Pharmacokinetic effects, such as genetic variation resulting 
in differences in activity in drug metabolising enzymes, can of 
course affect antipsychotic drug treatment by influencing plas-
ma concentrations and availability to the brain, or by affecting 
the synthesis of active metabolites. These effects may to some 
extent be compensated for by titration to an effective dose. 
Such pharmacokinetic factors represent one level of pharma-
cogenetic influence; three further pharmacodynamic levels of 
pharmacogenetic associations can be identified depending on 
the nature of the gene-drug interaction.
4 These influences in-
clude a) genes known or thought to be directly involved in 
the mechanisms of drug action, such as the dopamine D2 re-
ceptor, b) genes that may indirectly modify the primary drug 
mechanism, such as those involved in second messenger func-
tion or in interacting neurotransmitter systems and c) genes 
that are involved in disease pathology, such as dysbindin, or dise-
ase modification, such as catechol-O-methyltransferase (CO-
MT), and which may therefore determine how responsive the 
disease may be to pharmacotherapy. 
The starting point for pharmacogenetic investigation of tr-
eatment response, the phenotype, has in the past investigated 
variability in the DNA of one or a small number of “candidate” 
genes for study. Choice of candidate genes is hypothesis-driv-
en, whereby genes are usually selected on the basis of their cod-
ing for a protein that is known to be, or is potentially, involved 
in pharmacokinetic or pharmacodynamic aspects of drug ac-
tion. Identification of sites of common DNA variation in these 
genes, primarily single nucleotide polymorphisms (“SNPs”) 
or insertion/deletion sequences, provide the factors for associ-
ation of genotype with phenotype. 
Technological advance has resulted in the opportunity to in-
vestigate many (perhaps 1 million) SNPs across the whole ge-
nome and offer great power in identifying novel genetic as-
sociations unconstrained by prior hypotheses which, for the 
candidate gene approach, are inevitably founded on a limited 
understanding of the underlying mechanisms. These hypothe-
sis-free genome-wide association studies (GWAS) are not with-
out limitations; typically they select SNPs on the basis of po-
sition in the genome sequence, rather than as having known, 
or potential, functionality that may be chosen in candidate 
gene studies. They also have problems associated with the dif-
ficulties of data handling (where over 10
9 individual results 
may be accumulated) and consequent statistical analysis and 
interpretation.
CANDIDATE GENE STUDIES-FOCUS ON 
DOPAMINE AND SEROTONIN 
RECEPTORS
It is generally considered that the primary antipsychotic me-
chanism involves antagonist action at dopamine D2 recep-
tors in the brain. Thus polymorphisms in this gene (DRD2) 
have been widely investigated in respect of symptom resp-
onse, as have the related D2-like receptor genes DRD3 and 
DRD4. Similarly, the 5-HT2A receptor is a major drug target 
proposed to differentiate the atypical antipsychotics from the 
older drugs. 
The often inadequate effect of antipsychotic drugs on neg-
ative symptoms and cognitive deficits of schizophrenia, com-
pared to the response of positive symptoms, has been em-
phasised above. However, the pharmacological mechanisms 
that might underlie antipsychotic drug effects on negative and 
cognitive symptoms are far from clear. It has been suggested 
that drug action at 5-HT2A receptors is also responsible for 
some improved efficacy of the atypical antipsychotics on ne-
gative symptoms, although the supporting evidence for this 
clinical effect is very limited,
5 as is our understanding of the 
underlying mechanism. Nevertheless, there is some indication 
that 5-HT systems are involved in models of cognitive dys-
function in schizophrenia
6,7 as well as in symptom ameliora-
tion by newer antipsychotic drugs,
7 providing candidature in 
pharmacogenetic studies for HTR2A and other serotonergic 
genes such as HTR1A, HTR2C, HTR6 and HTT.
The first reports assessing genetic associations with antipsy-GP Reynolds
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chotic treatment response inevitably concentrated on the most 
obvious candidate genes with some replicated, if not totally 
consistent, findings of polymorphisms in three receptors: do-
pamine D2, dopamine D3 and serotonin 5-HT2A, being asso-
ciated with response to treatment (reviewed in 8, 9). The associ-
ation of the D2 receptor gene with response has been confirm-
ed more recently in a systematic review,
10 while overall associ-
ation of the D3 gene remains weak and inconsistent (e.g. 11, 
12). Other dopaminergic factors have been investigated in 
relation to drug response. The dopamine transporter (DAT) 
gene has shown both positive (with clozapine) and negative 
(with risperidone) association results,
13,14 but there are no con-
vincing findings indicating an influence of SNPs in the dopa-
mine D1 or D4 receptors on treatment response.
A review of association studies with SNPs in the 5-HT2A 
receptor gene concluded that results indicate some weak as-
sociation with antipsychotic response as well as with psycho-
sis itself.
15 Some further supporting data for the association 
with drug response has emerged from several more recent 
small studies including one employing the methodologically 
more rigorous transmission disequilibrium test.
16 Neverthe-
less the effect is a small one and not consistently obtained. The 
same is true for genes for other markers of serotonergic func-
tion. The serotonin transporter (HTT), with what is perhaps 
the most studied polymorphism in psychiatry, the insertion/
deletion (ins/del) sequence in the promoter region,
17 is asso-
ciated with antipsychotic response in some (e.g. 18, 19) but 
not all
20 studies. A SNP in the 5-HT1A receptor gene has also 
been shown to have effects on the response to antipsychotic tr-
eatment.
21-23 These HTT and HTR1A genes both code for pro-
teins that control presynaptic activity of the serotonin neuron; 
the major SNPs investigated in each case appear to directly in-
fluence gene expression. Thus promoter sequence HTT SNPs 
including the ins/del polymorphism of HTT and the SNP 
found in the insertion sequence,
24 influence HTT expression 
and activity, while the -1019C/G promoter SNP in HTR1A af-
fects a transcription factor binding site, again influencing ex-
pression levels and their control of the 5-HT1A receptor, as 
well as being associated with suicide and diagnosis of depres-
sion.
25
DIFFERENTIATING EFFECTS ON 
POSITIVE AND NEGATIVE SYNDROMES
In developing the opportunities for genetic testing, it seems 
more valuable to differentiate groups of symptoms in terms of 
their response to treatment. As mentioned above, the negative 
features of the disease respond poorly to antipsychotic drugs 
and it is these, rather than the positive symptoms, that are more 
important in determining functional recovery in patients. A 
minority of outcome studies have assessed separately the re-
sponses of positive and negative symptoms to drug treatment, 
despite the established differences in the effects of antipsycho-
tics on these symptom clusters. However, where this has been 
done, it appears that the majority of genes associated with 
positive symptom response are of dopamine receptors, while 
effects on negative symptoms are more associated with sero-
toninergic genes, in particular the 5-HT1A and 5-HT2A re-
ceptors.
4 Updating these initial observations, more recent re-
sults confirm the general association of genetic polymorphisms 
in dopamine systems with changes in positive symptoms, and 
serotonin with negative symptoms, with notably few anoma-
lies. Thus the previous finding of the association of negative 
symptom response has been confirmed for the HTR1A pro-
moter SNP
21,23 and identified for the HTT gene.
26 An associa-
tion with positive symptom response has been again confirm-
ed for the ser9gly functional DRD3 SNP
27 and intriguingly 
newly identified for the norepinephrine transporter gene.
28 
These results demonstrate relatively strong consistency, in 
spite of the substantial differences between samples in terms 
of treatment history (drug-naïve or previously-treated) and 
ethnicity. 
These findings may seem surprising on first sight, given the 
variety of different genes involved. However this multiplicity 
of genetic factors points to common mechanistic pathways; for 
example, changes in the expression and activity of both 5-HT1A 
receptors and the 5-HT transporter are likely to affect seroto-
nergic activity at the synapse, consequences of which may be 
mediated by post-synaptic receptors such as 5-HT2A. A si-
milar but unconfirmed observation has been seen for another 
5-HT receptor gene, HTR3E
29; notably the results for COMT 
indicate association solely with negative symptom improve-
ment (discussed below). Nevertheless the results strongly sug-
gest that the catecholamine and serotonin neurotransmitter 
systems are implicated separately in drug response of the two 
syndromes, while the exact mechanisms of their involvement 
remain elusive. Certainly there is evidence that selective se-
rotonin uptake inhibitors may be useful in the relief of nega-
tive symptoms in some patients.
30
There are some other genetic associations with drug-in-
duced changes in the more problematic negative and cognitive 
symptoms in schizophrenia. These include the val/met CO-
MT polymorphism,
31-33 which has a strong effect on enzyme 
activity and thereby influences dopamine (and norepinephrine) 
concentrations in the cortex where this enzyme, rather than 
neuronal transport, is primarily responsible for synaptic re-
moval of catecholamine neurotransmitters. The glutamate 
metabotropic receptor-3 gene, a further risk factor for schizo-
phrenia, has been reported as having SNPs associated with re-
sponse,
32 particularly of negative symptoms,
34 although a fol-4  Psychiatry Investig 2012;9:1-7
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lowing study showed an association not with negative symp-
tom response but with treatment-refractory schizophrenia.
35 
Dysbindin1, another gene with an established association with 
schizophrenia and implicated in neuronal and synaptic de-
velopment as well as dopamine receptor function, also shows 
association with treatment response in refractory schizo-
phrenia.
36
Few other pharmacogenetic studies have specifically ad-
dressed positive symptom improvement, although many ge-
netic associations with undifferentiated measures of symp-
tom response may primarily reflect the generally greater im-
provement in positive symptoms. The latest and strongest sin-
gle gene risk factor for schizophrenia, ZNF804A, is also re-
ported to be associated with positive symptom response.
37
In one study where a 5-HT1A gene SNP explained much of 
the variance in negative symptom response in first-episode pa-
tients,
22 there was also an association with depressive symp-
tom response, differentiated from that on negative symptoms. 
This is unsurprising, given the established association of this 
SNP with depression
25 and its treatment.
38 An association with 
depression as well as negative symptoms has been found for 
the 5-HT transporter gene in patients receiving antipsychotics, 
although the influence of treatment on this finding was not 
determined.
39 However it is notable that few pharmacogene-
tic studies have investigated separately the depression syn-
drome in schizophrenia, although it is an important deter-
minant of relapse in patients receiving antipsychotics.
40
CLOZAPINE RESPONSE
The unique efficacy of clozapine in the treatment of other-
wise non-responsive patients has resulted in clozapine being 
a prime target for pharmacogenetic investigation. Approxi-
mately 50% of patients not otherwise responding to antipsy-
chotic drug treatment benefit from clozapine; much early 
work on antipsychotic pharmacogenetics addressed this pro-
blem. A pharmacological basis for its clinical efficacy remains 
elusive; among the receptor mechanisms implicated, in addi-
tion to the 5-HT2A receptor antagonism common to most aty-
pical antipsychotics, are effects at alpha2 adrenoceptors, 5-HT1A 
receptors and dopamine D1 receptors, although no single re-
ceptor action is likely to explain clozapine’s action in full.
41
In some early work Arranz et al.
42 studied a range of candi-
date genes, primarily chosen on the basis of the known phar-
macology of clozapine. They looked for association of re-
sponse with 19 polymorphisms in 10 genes associated with 
monoamine neurotransmission; six polymorphisms together 
gave a (retrospective) sensitivity of 96% in identifying clo-
zapine responders. The strongest components in this profile 
of polymorphisms were two SNPs in the HTR2A gene: one 
synonymous (silent) 102T/C in linkage disequilibrium with 
a promoter SNP (-1438A/G) with functional activity
43 and one 
nonsynonymous his452tyr. These findings have not been con-
sistently replicated
9 but they nevertheless led to the establish-
ment of a pharmacogenetic test for clozapine response, al-
though this is no longer available. A confirmatory prospective 
trial to assess the predictability and value in practice of such 
pharmacogenetic testing for drug response has yet to be un-
dertaken. Reflecting our incomplete understanding of the 
mechanism of clozapine’s action, a consistent pharmacogenet-
ic finding that might relate selectively to clozapine response 
still eludes us. Many pharmacogenetic studies, including sev-
eral cited in this chapter, have been carried out on cohorts of 
clozapine-treated subjects as well as those receiving other an-
tipsychotic drugs,
44 but as yet there is no reliable evidence for 
distinct clozapine-specific pharmacogenetic associations with 
response.
OTHER GENETIC ASSOCIATIONS WITH 
RESPONSE - CANDIDATE GENES TO 
GWAS
The positive and replicated findings with SNPs in dopa-
mine and serotonin genes, reviewed more extensively elsewh-
ere,
45 are reassuring in terms of our very limited understand-
ing of pharmacological mechanisms. However they are are st-
rongly influenced by a research bias towards testing these 
more obvious hypotheses and unfortunately do not consis-
tently emerge from GWAS, as discussed below. Variation in 
these genes can usually only explain a small percentage of the 
variance in response, and further factors inevitably contrib-
ute to antipsychotic-induced improvement in symptoms. 
Those other genetic factors might include SNPs in a wide va-
riety, perhaps many hundreds, of genes potentially influenc-
ing neuronal function, including other neurotransmitter re-
ceptors, enzymes and transporters, as well as second messenger 
systems or signalling pathways. Just one of many examples is 
the SNP in the G-protein beta3 subunit gene (GNB3), involv-
ed in receptor signal transduction, and which reportedly shows 
weak association with symptom response to antipsychotic tr-
eatment.
46-48 However, there are few associations with symp-
tom response outside the genes involving dopamine and se-
rotonin systems that have yet been consistently replicated.
The independent and influential CATIE trial of the relative 
effects of several antipsychotic drugs
5 has been very valuable 
in provide a large set of data on the consequences of treatment 
of a carefully controlled and rigorously assessed sample of 
people with schizophrenia. Although it is not without limita-
tions, pharmacogenetic studies from this trial are beginning to 
yield interesting and novel findings. GP Reynolds
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An investigation of a large series of 118 candidate genes
49 
identified several significant associations with change in the 
Positive and Negative Syndrome Scale (PANSS) in the CATIE 
sample, the numbers of which were roughly in line with the 
expected false discovery rate (22 of 2769 SNPs reached signi-
ficance at p<0.01). Seven of the significant SNPs were in gluta-
mate receptor genes, which might be of more interest were it 
not for the fact that such genes were represented by over 1000 
of the SNPs studied. This choice of candidates clearly reflects 
the increasing evidence of the importance of glutamate neuro-
transmission in in the pathology of schizophrenia
50 particular-
ly in relation to cognitive dysfunction.
51 Nevertheless the au-
thors also identified significant association with SNPs on 
HTR2A, DRD3, the nicotinic receptor alpha
7 subunit gene 
and the excitatory amino acid transporter 4 gene (SLC1A6), 
among other candidates. None of the significant findings cl-
early differentiated effects on positive and negative symptoms. 
In their investigation of association with cognitive outcomes, 
some interesting findings emerged, again with strong contribu-
tions from glutamate receptors but also identifying effects of 
genes for the 5-HT4 receptor and for a neuronal adenylate cy-
clase.
49
A GWAS study of the same sample has provided very differ-
ent results, with the strongest effect on change in PANSS sh-
own with a SNP in an inter-gene sequence on chromosome 
4; other novel results close to the significance threshold were 
in ANKS1B, CNTNAP5 and TRPM1, all of which are poten-
tially involved in neuronal development or neurotransmis-
sion.
52 How exactly they might be involved in drug response 
is far from clear, however; certainly replication as candidate 
genes in other samples is needed. The same group has looked 
at neurocognition as an outcome measure of response in this 
series,
53 finding significance in several genes of which the top 
two are EHF (a transcription factor with little evidence for a 
neuronal role) and SLC26A9 (a chloride ion transporter). In-
terpretation of these findings is not straightforward, although 
more reassuring are the findings of (somewhat weaker) asso-
ciation with DRD2 and ANKS1B, the latter found also to be 
associated with negative symptom response in the previous 
analysis.
A further study of the CATIE sample employed a theoreti-
cal model-based approach
54 which found that several SNPs 
in the developmental gene EN1 (engrailed1) are associated 
with antipsychotic response. This study used data sets for 
schizophrenia risk genes and for mouse SNPs affecting pre-
pulse inhibition of the startle reflex, a physiological effect which 
is consistently deficient in schizophrenia and reversed by an-
tipsychotic drug treatment, to generate candidates for study 
in the CATIE database, of which only EN1 was found to be 
significant.
There have been other approaches using such unbiased in-
dependent methods to select candidate genes. Homer-1, a 
gene associated with glutamatergic transmission and identifi-
ed as a candidate from animal studies of gene expression fol-
lowing haloperidol administration, shows SNP associations 
with response to treatment.
55 An equivalent approach
56 inves-
tigated changes in gene expression following risperidone ad-
ministration to mice which were compared with findings from 
a GWAS of response to risperidone treatment. This identified 
several novel candidates, of which PDE-7 was found to have 
association both with disease, internally replicated, and with 
treatment response. Unfortunately, despite the apparent va-
lidity of these two approaches, there appears to be little con-
sistency between them. Such criticism, to which much of the ph-
armacogenetic literature is susceptible, can always be coun-
tered by highlighting the differences between study samples 
in ethnicity, drug treatment and other such factors, but it re-
mains a problem for the generalizability of any findings.
Iloperidone, an antipsychotic that was recently approved in 
the USA, underwent substantial pharmacogenetic study dur-
ing its phase III trials. One investigation involved a GWAS that 
identified six SNPs in six genes associated with drug treatment 
response
57; this data was re-analaysed in a retrospective as-
sessment to identify response-dependent genetic subgroups 
of patients.
58 How specific these findings are to iloperidone 
remains unclear; these authors report that the six SNPs iden-
tified did not significantly associate with ziprasidone resp-
onse, although another group observed that two of the genes 
(XKR4 and GRIA4) were also associated with risperidone res-
ponse.
59 
CONCLUSIONS
For more than the past decade much effort has been spent 
in attempting to determine the genetic predictors of the effects 
of antipsychotic drugs, particularly in their positive effects 
on symptom response. It is clear that, despite this effort, iden-
tification of the major genetic contributors to the consequenc-
es of antipsychotic drug treatment still eludes us. There is a st-
riking paucity of consistently reproducible findings in the 
pharmacogenetic studies reported. There are many reasons for 
this. One particularly important factor is that many studies 
are underpowered to identify what are often relatively small 
effects; this will inevitably introduce variability of results be-
tween studies. Other factors include differences in sample 
ethnicity, with the inevitable differences in genetic make-up 
between different ethnic samples. Different drug treatments 
may be associated with different pharmacogenetic influences, 
although it is important to note that, contrary to some sugges-
tions in the literature, there is so far little evidence for truly 6  Psychiatry Investig 2012;9:1-7
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drug-specific genetic associations. Other differences between 
samples may introduce inconsistencies; the response to treat-
ment in first-episode and previously drug naïve patients may 
well differ in underlying pharmacological mechanisms from 
equivalent effects in patients with a chronic treatment history, 
resulting in different pharmacogenetic associations. Further-
more the clinical phenotypes measured may often be com-
plex and multifactorial, composed of several physiological re-
sponses under different genetic control mechanisms, of which 
the negative and positive syndromes provide just one example. 
It should of course be remembered that symptom response 
to drug treatment is inevitably dependent on treatment adher-
ence, and thus factors influencing compliance, such as unwant-
ed side effects, will also be important in determining good re-
sponse. Genetic factors also influence the emergence of ad-
verse drug effects, and thus pharmacogenetic associations 
relating to the side effects of antipsychotic treatment, which 
have not been reviewed here, may indirectly contribute to the 
pharmacogenetic factors influencing symptom response.
Future work will need to overcome these many limitations 
and discrepancies reported in the current literature. There is 
need for a greater recognition of the potential importance of 
gene-gene interactions and, as is increasingly apparent in un-
derstanding disease pathogenesis, gene-environment inter-
actions in understanding properly the risk factors contribut-
ing to poor response to antipsychotic treatment. 
Nevertheless, the pharmacogenetics of antipsychotic drugs 
has progressed enormously, and new findings are beginning 
to take us towards a better understanding of the mechanisms 
underlying the effects of these drugs. As the technology devel-
ops and genotyping of large numbers of SNPs in large samples 
becomes cheaper and more accessible, findings from further 
GWAS studies will, we hope, converge to give us consistent re-
sults. Identifying such results will open up opportunities for 
predictive genetic testing, once their validity and, importantly, 
utility in the clinic are established.
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